multiple sclerosis

After a long, painful revamp, Merck KGaA scores key OK for once-defunct MS drug cladribine
After a long, painful revamp, Merck KGaA scores key OK for once-defunct MS drug cladribine
Endpoints
Merck KGaA
MS
multiple sclerosis
cladribine
Flag link:
Drug blocked by European regulators improves quality of life for MS patients
Drug blocked by European regulators improves quality of life for MS patients
Drug Delivery Business News
Europe
MS
multiple sclerosis
cladribine
Flag link:
Lawmakers dig into 'skyrocketing' MS costs with probe into 7 drugmakers
Lawmakers dig into 'skyrocketing' MS costs with probe into 7 drugmakers
Fierce Pharma
multiple sclerosis
MS
drug pricing
Bayer
Biogen
Merck KGaA
Novartis
Sanofi
Teva Pharmaceutical
Roche
Flag link:
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Investors Business Daily
MS
multiple sclerosis
Roche
Celgene
Novartis
Biogen
ozanimod
Gilenya
Ocrevus
Extavia
Flag link:
How Biogen Inc. Makes Most of Its Money
How Biogen Inc. Makes Most of Its Money
Motley Fool
Biogen
Tecfidera
Tysabri
MS
multiple sclerosis
Flag link:
EMA Restricts Use of Biogen MS Drug
EMA Restricts Use of Biogen MS Drug
RAPS.org
Europe
EMA
Biogen
MS
multiple sclerosis
Zinbryta
Flag link:
Biogen aims to block Tecfidera generics with flurry of lawsuits
Biogen aims to block Tecfidera generics with flurry of lawsuits
Bizjournals.com
Biogen
Tecfidera
generics
MS
multiple sclerosis
Novartis
Sandoz
Mylan Labs
Flag link:
2 Pharma Buyout Targets That May Surprise You
2 Pharma Buyout Targets That May Surprise You
Motley Fool
Biogen
Bristol-Myers Squibb
M&A
MS
multiple sclerosis
immuno-oncology
Flag link:
Roche's Ocrevus racks up more positive MS data in relapsing and primary progressive forms
Roche's Ocrevus racks up more positive MS data in relapsing and primary progressive forms
Fierce Pharma
Roche
Ocrevus
MS
multiple sclerosis
Flag link:
EMA Recommends New HCV, Cancer and MS Drugs for Approval
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Europe
EMA
hepatitis C
multiple sclerosis
breast cancer
renal cell carcinoma
AbbVie
Maviret
Gilead Sciences
Vosevi
Biogen
Amgen
Samsung Bioepis
biosimilars
Humira
Novartis
Kisqali
EUSA
Fotivda
Flag link:
Mylan's Copaxone copy could face another hold-up with FDA info request
Mylan's Copaxone copy could face another hold-up with FDA info request
Fierce Pharma
Mylan
Copaxone
FDA
generics
Teva Pharmaceutical
MS
multiple sclerosis
Flag link:
Roche looks into PML report for Ocrevus patient
Roche looks into PML report for Ocrevus patient
BioPharma Dive
Roche
PML
Ocrevus
Genentech
MS
multiple sclerosis
Flag link:
Celgene touts ozanimod MS data, but disability benefit weak over rival med
Celgene touts ozanimod MS data, but disability benefit weak over rival med
Fierce Biotech
Celgene
ozanimod
MS
multiple sclerosis
Biogen
Avonex
Flag link:
Teva crashes out of laquinimod MS program
Teva crashes out of laquinimod MS program
BioPharma Dive
Teva Pharmaceutial
MS
multiple sclerosis
laquinimod
Flag link:
Troubled Teva’s successor to Copaxone just failed a big PhIII test for multiple sclerosis
Troubled Teva’s successor to Copaxone just failed a big PhIII test for multiple sclerosis
Endpoints
Teva Pharmaceutical
Copaxone
MS
multiple sclerosis
laquinimod
Active Biotech
Flag link:
Celgene highlights MS drug in diversification push
Celgene highlights MS drug in diversification push
BioPharma Dive
Celgene
MS
multiple sclerosis
ozanimod
Flag link:
Novartis' Gilenya patent loss sets MS market up for battle with early generics
Novartis' Gilenya patent loss sets MS market up for battle with early generics
Fierce Pharma
Novartis
Gilenya
MS
multiple sclerosis
generics
Flag link:
4 Reasons Why Roche Will Have the Best Growth in Big Pharma... and 1 Reason Why It Won't
4 Reasons Why Roche Will Have the Best Growth in Big Pharma... and 1 Reason Why It Won't
Motley Fool
Roche
Tecentriq
Perjeta
HER-2 postive breast cancer
Ocrevus
MS
multiple sclerosis
diagnostics
generics
biosimilars
Flag link:
Bass Battled U.S. Drug Patents and Prices But Lost to ‘Cabal’
Bass Battled U.S. Drug Patents and Prices But Lost to ‘Cabal’
Bloomberg
Kyle Bass
patents
drug pricing
AMPYRA
Acorda Therapeutics
multiple sclerosis
Flag link:
Why Roche's New Drug Is Bad News For Biogen
Why Roche's New Drug Is Bad News For Biogen
Barron's
Roche
Biogen
Ocrevus
multiple sclerosis
MS
Tysabri
Tecfidera
Flag link: